LOCAMETZ Drug Patent Profile
✉ Email this page to a colleague
When do Locametz patents expire, and what generic alternatives are available?
Locametz is a drug marketed by Novartis and is included in one NDA. There are two patents protecting this drug.
This drug has fifty-six patent family members in sixteen countries.
The generic ingredient in LOCAMETZ is gallium ga-68 gozetotide. There are sixteen drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the gallium ga-68 gozetotide profile page.
DrugPatentWatch® Generic Entry Outlook for Locametz
Indicators of Generic Entry
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for LOCAMETZ?
- What are the global sales for LOCAMETZ?
- What is Average Wholesale Price for LOCAMETZ?
Summary for LOCAMETZ
| International Patents: | 56 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Drug Prices: | Drug price information for LOCAMETZ |
| What excipients (inactive ingredients) are in LOCAMETZ? | LOCAMETZ excipients list |
| DailyMed Link: | LOCAMETZ at DailyMed |
US Patents and Regulatory Information for LOCAMETZ
LOCAMETZ is protected by two US patents.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | LOCAMETZ | gallium ga-68 gozetotide | POWDER;INTRAVENOUS | 215841-001 | Mar 23, 2022 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Novartis | LOCAMETZ | gallium ga-68 gozetotide | POWDER;INTRAVENOUS | 215841-001 | Mar 23, 2022 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for LOCAMETZ
When does loss-of-exclusivity occur for LOCAMETZ?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 08289108
Estimated Expiration: ⤷ Start Trial
Canada
Patent: 96627
Estimated Expiration: ⤷ Start Trial
China
Patent: 2014956
Estimated Expiration: ⤷ Start Trial
Patent: 4873982
Estimated Expiration: ⤷ Start Trial
Denmark
Patent: 87965
Estimated Expiration: ⤷ Start Trial
European Patent Office
Patent: 87965
Estimated Expiration: ⤷ Start Trial
Patent: 88086
Estimated Expiration: ⤷ Start Trial
Patent: 56403
Estimated Expiration: ⤷ Start Trial
Patent: 31380
Estimated Expiration: ⤷ Start Trial
Patent: 38298
Estimated Expiration: ⤷ Start Trial
Patent: 58347
Estimated Expiration: ⤷ Start Trial
Patent: 64384
Estimated Expiration: ⤷ Start Trial
Hong Kong
Patent: 12588
Estimated Expiration: ⤷ Start Trial
Hungary
Patent: 47200
Estimated Expiration: ⤷ Start Trial
Israel
Patent: 3998
Estimated Expiration: ⤷ Start Trial
Japan
Patent: 02237
Estimated Expiration: ⤷ Start Trial
Patent: 96479
Estimated Expiration: ⤷ Start Trial
Patent: 25690
Estimated Expiration: ⤷ Start Trial
Patent: 38118
Estimated Expiration: ⤷ Start Trial
Patent: 79355
Estimated Expiration: ⤷ Start Trial
Patent: 09824
Estimated Expiration: ⤷ Start Trial
Patent: 61049
Estimated Expiration: ⤷ Start Trial
Patent: 10536790
Estimated Expiration: ⤷ Start Trial
Patent: 14221779
Estimated Expiration: ⤷ Start Trial
Patent: 16153410
Estimated Expiration: ⤷ Start Trial
Patent: 18058864
Estimated Expiration: ⤷ Start Trial
Patent: 18150350
Estimated Expiration: ⤷ Start Trial
Patent: 20073472
Estimated Expiration: ⤷ Start Trial
Patent: 21075561
Estimated Expiration: ⤷ Start Trial
Patent: 22110118
Estimated Expiration: ⤷ Start Trial
Patent: 24117783
Estimated Expiration: ⤷ Start Trial
New Zealand
Patent: 3931
Estimated Expiration: ⤷ Start Trial
Patent: 0085
Estimated Expiration: ⤷ Start Trial
Poland
Patent: 87965
Estimated Expiration: ⤷ Start Trial
Portugal
Patent: 87965
Estimated Expiration: ⤷ Start Trial
Slovenia
Patent: 87965
Estimated Expiration: ⤷ Start Trial
Spain
Patent: 68224
Estimated Expiration: ⤷ Start Trial
Patent: 30116
Estimated Expiration: ⤷ Start Trial
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering LOCAMETZ around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 2008289108 | ⤷ Start Trial | |
| Canada | 2696627 | ⤷ Start Trial | |
| China | 102014956 | ⤷ Start Trial | |
| China | 104873982 | ⤷ Start Trial | |
| Denmark | 2187965 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch